AlphAIAlphAI — Financial news for AI agents
sharecast.comOCT 192 min read$GSK

GSK's Ris‑Rez shows 61pc response rate in early lung cancer study

GSK reported that its drug Ris-Rez showed a 61% response rate at 8mg/kg dose in a phase Ib study, higher than the 32% at 6mg/kg. The company plans to use the 8mg/kg dose in its ongoing phase III trial. GSK noted manageable side effects, with serious issues in 42% of higher-dose patients. The results will be presented at the ESMO 2026 congress. As of 0905 BST, GSK shares were up 0.16% at 1,865.50p.

Original reporting
sharecast.com
Published Oct 19, 2026, 8:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
GSK's Ris‑Rez shows 61pc response rate in early lung cancer study — source image
Source · sharecast.com
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The data could improve market perception of GSK's oncology franchise and affect upcoming Phase III trial expectations.

02

Market read

First report of significant efficacy data; likely to generate modest price movement.

03

What to watch

Long‑term survival benefit and Phase III design details remain unknown.

Relevance 7/10Novelty 8/10Timing: today

Background

GSK announced early Phase Ib results for its experimental lung‑cancer drug Ris‑Rez, with a higher dose showing a 61% response rate.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

Phase Ib data shows 61% response at 8 mg/kg versus 32% at 6 mg/kg, new trial result first reported.

Expected impact

modest upside as market prices in the improved response rate

Evidence & confidence

First disclosure of statistically better efficacy at the higher dose, with manageable safety, is material for investors.

Market effects

Sector

strengthens the oncology pipeline outlook for large pharma

Regional

UK and European pharma stocks may see modest gains

Global

potentially influences global biotech sentiment

Counterpoint

What could challenge this read

Some investors may view the side‑effect rates as a risk that could temper price gains.

Key entities

  • company
    GSK

    FTSE 100‑listed pharmaceutical company

  • drug
    Ris‑Rez

    Experimental treatment for extensive‑stage small cell lung cancer

Read at source← All news

StoryGSK reports 61% response rate for Ris‑Rez in early global small‑cell lung‑cancer trial

Also covered by

3 outlets

Related articles

OCT 19
$GSKHighAI 8/10

GSK hails "positive" data; Volex in record half-year

GSK reported positive results from a drug trial for small cell lung cancer, with an 8mg/kg dose showing a 61% objective response rate. LondonMetric reported an 8% increase in net rental income to GBP240 million for the first half. Volex expects record half-year revenue of at least USD710 million, up 22% year-over-year, and annual profit at the upper end of market forecasts. ITM Power narrowed its annual loss to GBP24.8 million, with revenue up 68% to GBP43.6 million.

marketscreener.com2 min
OCT 19
$GSKMedAI 8/10

GSK Reports 61% Response Rate in First Global Ris-Rez Lung Cancer Data

GSK reported a 61% response rate for its experimental lung cancer drug Ris-Rez in a phase Ib study, with 8 mg/kg dose showing higher efficacy but more severe side effects. The data, presented at ESMO Congress, support a global phase III trial. GSK aims for 40+ indications by 2040, though the results are not an immediate earnings driver.

asktraders.com2 min